OmniAb, Inc.

PEGS Europe is here and the OmniAb team is in Barcelona for all the action. Stop by Booth 1202 and get the latest on how we're pushing antibody discovery to new heights with our in vivo and in silico platforms. Join us for presentation with Phil Leighton as he talks about the OmnidAb platform, a chicken engineered to express single domain antibodies in an optimized human framework. Learn more: https://lnkd.in/gbmEZMap

The OmniAb team is in San Diego for World ADC 2024! Join us tomorrow for a presentation with our VP of Preclinical R&D, Eric Vajda, to learn how OmniAb’s suite of antibody discovery capabilities are well-suited to ADCs. Get the details here: https://lnkd.in/g2mEx9x6

OmniAb to Participate in Two Investor Conferences in November https://lnkd.in/gy_AWvwG

Today, the Computational Drug Development Summit kicks off in Boston! Stop by our presentation tomorrow to learn about our suite of in silico tools that give deep insights into vast antibody repertoires. See you there! https://lnkd.in/giiFS2fb

OmniAb to Report Third Quarter 2024 Financial Results on November 12 https://lnkd.in/g8yhzrJh 

OmniAb is in Kyoto this week for Antibody Engineering & Therapeutics Asia. Visit our team in Booth 23 and join us for a presentation tomorrow with Bill Harriman, PhD to learn how OmniAb accesses the biodiversity of six species to generate high-quality custom repertoires of human antibodies. Learn more: https://lnkd.in/g-5ptcQ3 #AntibodyEng

In celebration of STEM Day, the OmniAb Women’s Network for STEM (OWN STEM) had the incredible opportunity to welcome high school students for an up-close experience with OmniAb's high throughput screening tools, including GEM and xPloration®. Together, we’re empowering the next generation of innovators, engineers, scientists, and creators. Thank you to everyone who made this event possible, including our community partners at Berkeley Lab.

OmniAb’s CEO Matt Foehr joined industry leaders from Gilead, Inimmune, Medable and NVIDIA at the Bio Investor Forum in San Francisco this afternoon for a panel discussion on “AI Productivity Enhancements for Developing Assets.” The panel, moderated by Ruchita Sinha of AV8 Ventures, discussed the importance of AI-related productivity enhancements that leading biotechs are using to discover and develop new drugs. #BIF24

We are in Basel this week for the Festival of Biologics! Come see Christel Iffland’s presentation on AI-powered bispecific antibody discovery tomorrow: https://lnkd.in/gdZDuaR7 Our team will be in Booth 822, stop by! 

We're happy to be back in Boston for Discovery on Target! Visit the OmniAb team at Booth 505 and join us for a luncheon presentation tomorrow at 12:10 pm to hear about our advanced antigen design capabilities. See you there: https://lnkd.in/gAepnNs8 #BostonDOT24